Nykode Therapeutics to Showcase APC-Targeted DNA Vaccine Platform at 3rd Annual Personalized Cancer Vaccine Summit

On November 19, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer vaccines, reported that Chief Executive Officer, Michael Engsig, and Chief Scientific Officer and Co-founder, Agnete Fredriksen, will participate in the 3rd Annual Personalized Cancer Vaccine Summit, taking place December 1–3, 2026 in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nykode’s leadership will contribute to three sessions during the summit, sharing the company’s perspectives on the development, manufacturing, and clinical translation of personalized cancer vaccines.

"As interest in the field of individualized neoantigen cancer vaccines continues to grow, attention is increasingly turning to how these treatments can be delivered to patients at scale," said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode Therapeutics. "We believe our APCtargeted DNA platform offers a differentiated approach, supported by encouraging clinical immunogenicity data and an established manufacturing process. We look forward to contributing to discussions on the opportunities and challenges shaping the future of personalized cancer vaccines."

Nykode’s work in personalized cancer vaccines is being advanced through VB10.NEO, its wholly owned, DNA-based individualized neoantigen therapy (INT). Built on Nykode’s proprietary antigenpresenting cell (APC)-targeting technology and NeoSELECT, its AI-driven neoantigen selection engine, VB10.NEO is designed to deliver selected antigens to APCs to generate broad, potent, and long-lasting antigen-specific immune responses.

The company has established an end-to-end manufacturing process for VB10.NEO, achieving 100% manufacturing success across two clinical trials. Further optimization of the manufacturing process reduces the current turnaround-time from biopsy to product release to less than six weeks with a clear path to further reductions by additional consolidation under "one roof". Its plasmid DNA-based platform also offers potential advantages in manufacturing complexity, and cost of goods compared with alternative approaches.

Clinical data across two trials in patients with advanced solid tumors have demonstrated vaccinespecific immune responses in 88–100% of patients, including de novo T-cell responses in 85% of patients. These responses remained durable for more than one year after the final dose, supporting the potential of Nykode’s platform to generate strong and sustained immune responses.

Summit Program and Presentation Details

1. Workshop: Streamlining Manufacturing, Analytics & Supply Chain Operations to Accelerate
Delivery of Personalized Cancer Vaccines
Speaker: Michael Engsig
Date: Tuesday, December 1, 2026
Time: 9:00 a.m.

2. Seminar: From Promise to Practice: Enabling the Next Generation of Personalized Cancer
Vaccines
Speaker: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 9:00 a.m

3. Panel Discussion: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose
the Right Strategy for the Right Indication
Panelist: Agnete Fredriksen
Date: Thursday, December 3, 2026
Time: 11:30 a.m.

(Press release, Nykode Therapeutics, NOV 19, 2026, View Source [SID1234675038])